[1]张栓宝,张燕平△,严宁娟.康莱特注射液对乳腺癌新辅助化疗患者免疫功能、血管内皮生长因子及生活质量的影响[J].陕西中医,2019,(11):1566-1569.
　ZHANG Shuanbao,ZHANG Yanping,YAN Ningjuan..Effect of Kanglaite injection on immune function,VEGF and quality of life in patients with breast cancer receiving neoadjuvant chemotherapy[J].,2019,(11):1566-1569.
点击复制

康莱特注射液对乳腺癌新辅助化疗患者免疫功能、血管内皮生长因子及生活质量的影响
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2019年11期
页码:
1566-1569
栏目:
临床研究
出版日期:
2019-11-05

文章信息/Info

Title:
Effect of Kanglaite injection on immune function,VEGF and quality of life in patients with breast cancer receiving neoadjuvant chemotherapy
文章编号:
DOI:10.3969/j.issn.10007369.2019.11.022
作者:
张栓宝1; 张燕平2△; 严宁娟3
1.西电集团医院（西安 710000）；2.西安市莲湖区桃园社区卫生服务中心（西安 710077）；3.中国中医科学院望京医院（北京 100102）
Author(s):
ZHANG Shuanbao; ZHANG Yanping; YAN Ningjuan.
Xi’an XD Group Hospital(Xi’an 710000）
关键词:
康莱特注射液; 乳腺癌; 新辅助化疗; 免疫功能; VEGF; 生活质量
Keywords:
Key words Kanglaite injection; Breast cancer; Neoadjuvant chemotherapy; Immune function; VEGF; Quality of life
分类号:
R737.9
文献标志码:
A
摘要:
摘要目的：研究康莱特注射液对乳腺癌新辅助化疗患者免疫功能、血管内皮生长因子（VEGF）及生活质量的影响。方法：纳入拟行乳腺癌改良根治术的120例乳腺癌患者，按照随机数字表法将患者分为对照组和康莱特组，各60例。对照组患者于乳腺癌改良根治术前进行新辅助化疗，观察组在对照组的基础上使用康莱特注射液。比较两组患者化疗前后的免疫功能变化，比较两组患者化疗前后的血管内皮生长因子（VEGF）的变化，使用乳腺癌患者生存质量测定量表对两组患者化疗后的生活质量进行评估，评价两组患者在新辅助化疗期间的不良反应，包括粒细胞减少、恶心呕吐、发热和血小板减少的发生率。结果：与化疗前相比，化疗后对照组CD8+、CD4+、CD3+水平变化无统计学意义（P＞005），化疗后康莱特组CD8+水平明显降低（P＜005），CD4+和CD3+水平明显上升（P＜005）。与化疗前相比，对照组和康莱特组VEGF水平均呈现显著下降趋势（P＜005），其中与对照组相比，康莱特组变化更大（P＜005）。化疗后，与对照组相比，康莱特组的生理状况、社会/家庭状况、情感状况、功能状况、睡眠状况和依从状况均明显较低（P＜005）。康莱特组粒细胞减少、恶心呕吐、发热和血小板减少的发生率明显低于对照组（P＜005）。结论：乳腺癌患者新辅助化疗的过程中使用康莱特注射液，能够有效改善患者机体免疫力，抑制肿瘤生长和增殖，提高患者生活质量，且安全性较高。
Abstract:
AbstractObjective：To study the effects of Kanglaite injection on immune function,VEGF and quality of life in neoadjuvant chemotherapy for breast cancer patients.Methods： A total of 120 breast cancer patients who underwent modified radical mastectomy were enrolled.The patients were divided into control group and Kanglaite group according to the random number table method,60 cases each.The control group underwent neoadjuvant chemotherapy before modified radical mastectomy,and the observation group used Kanglaite injection on the basis of the control group.The changes of immune function before and after chemotherapy were compared between the two groups.The changes of vascular endothelial growth factor (VEGF) before and after chemotherapy were compared between the two groups.The quality of life of the two groups of patients after chemotherapy was assessed using the breast cancer patient quality of life scale.Adverse reactions during neoadjuvant chemotherapy,including neutropenia,nausea and vomiting,fever,and thrombocytopenia,were evaluated in both groups.Results：Compared with before chemotherapy,the levels of CD8+,CD4+ and CD3+ in the control group after chemotherapy were not statistically significant (P＞005).After chemotherapy,the level of CD8+ in Kanglaite group was significantly decreased (P＜005),and the levels of CD4+ and CD3+ were significantly increased (P＜005).Compared with prechemotherapy,the VEGF levels in the control group and Kanglaite group showed a significant decrease (P＜005),and the change in the Kanglaite group was greater than that in the control group (P＜005).After chemotherapy,compared with the control group,the physiological status,social/family status,emotional status,functional status,sleep status and compliance of the 〖LM〗Kanglaite group were significantly lower (P＜005).The incidence of neutropenia,nausea and vomiting,fever and thrombocytopenia was significantly lower in Kanglaite than in the control group (P＜005).Conclusion：The use of Kanglaite injection in the process of neoadjuvant chemotherapy for breast cancer patients can effectively improve the body immunity,inhibit tumor growth and proliferation,improve the quality of life of patients,and has high safety,which is worthy of popularization and application in clinic.

参考文献/References:

[1]唐小燕,郎荣刚,付丽.乳腺癌新辅助化疗效果的病理评估[J].中华乳腺病杂志：电子版,2018,12(5):257262.
[2]景俊杰,李小玲,南月清.康莱特注射液对肿瘤治疗的作用研究进展[J].中国药物与临床,2013,13(11):14471448.
[3]中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2015版)[J].中国癌症杂志,2015,25(9):692754.
[4]左婷婷,陈万青.中国乳腺癌全人群生存率分析研究进展[J].中国肿瘤临床,2016,43(14):639642.
[5]罗勇,李崎,华特波.新辅助化疗联合乳腺癌改良根治术对乳腺癌患者免疫功能、基质金属蛋白酶及血管内皮生长因子的影响[J].中国临床药理学与治疗学,2018,23(1):104109.
[6]张崇建,秦丽,王璐,等.乳腺癌新辅助化疗疗效的影响因素及预后分析[J].中国老年学杂志,2016,36(3):636637.
[7]王乐,陈晨,张洪峰,等.康莱特注射液上市后临床安全性医院集中监测研究[J].环球中医药,2016,9(3):372373.
[8]王玉娟.康莱特注射液联合新辅助化疗方案治疗肺癌的疗效及其对细胞凋亡和增殖的影响[J].广西医科大学学报,2017,34(2):218221.
[9]冯瑜,汪敏.康莱特注射液联合索拉非尼、IL2治疗晚期肾癌临床疗效及对患者免疫功能的影响[J].陕西中医,2017,38(4):463464.
[10]马文龙,严亚峰,王小平.康莱特注射液配合化疗对肝癌的疗效及免疫系统的影响[J].国际免疫学杂志,2017,40(4):409.
[11]吴冬娣.P53、VEGF在乳腺癌新辅助化疗前后的表达意义及相关性分析[D].南昌：南昌大学,2017.
[12]王媛,惠双,李敏,等.康莱特注射液用于吉西他滨联合顺铂方案化疗晚期非小细胞肺癌的临床研究[J].中国临床药理学杂志,2017,33(23):23542356.
[13]董爱萍,韩良浩.乳腺癌患者生活质量测评量表及其应用[J].肿瘤,2017,37(1):114123.
[14]王丰莲,楚爱景.康莱特注射液联合化疗治疗乳腺癌患者的疗效与安全性观察[J].内科,2018,13(1):9092.
[15]李向东,董灵.康莱特注射液联合化疗对晚期非小细胞肺癌生活质量及骨髓抑制的影响[J].河北医学,2016,22(4):543545.

相似文献/References:

[1]陈 楠,王光辉△,贺 赛,等.养正合剂改善乳腺癌术后化疗者不适及对患者细胞因子、红细胞免疫的影响[J].陕西中医,2019,(10):1357.
　CHEN Nan,WANG Guanghui,HE Sai,et al.Yangzheng mixture improves the discomfort of postoperative chemotherapy in patients with breast cancer and its immunity to cytokines and red blood cells[J].,2019,(11):1357.
[2]张贺,姜大庆.鸦胆子素D对乳腺癌MDAMB231细胞增殖与凋亡及细胞周期的影响*[J].陕西中医,2019,(11):1495.
　ZHANG He,JIANG Daqing..Effects of Bruceine D on proliferation,apoptosis and cell cycle of breast cancer MDAMB231 cells[J].,2019,(11):1495.
[3]贺晓立,王 军,余 静,等.沈力教授治疗乳腺癌十一法*[J].陕西中医,2020,(1):92.
　HE Xiaoli,WANG Jun,YU Jing,et al.Professor SHEN Li’s treatment of breast cancer by using eleven TCM methods[J].,2020,(11):92.
[4]刘歆春,李锁南,黄飞燕.乳岩汤联合西药治疗乳腺癌疗效及对患者免疫功能的影响[J].陕西中医,2021,(9):1201.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.012]
[5]冯秀梅,马 兰,罗玉群,等.益气活血方对乳腺癌MCF-7细胞系增殖侵袭能力及miR-100表达水平影响的研究[J].陕西中医,2021,(11):1527.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.007]
　FENG Xiumei,MA Lan,LUO Yuqun,et al.Yiqi Huoxue recipe to inhibit breast cancer cell proliferation and invasion and increase the expression of miR-100[J].,2021,(11):1527.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.007]
[6]陈 军,孙 嫘,惠建荣,等.艾灸对三阴性乳腺癌移植瘤小鼠生存期的影响及机制研究[J].陕西中医,2022,(7):819.[doi:DOI:10.3969/j.issn.1000-7369.2022.07.001]
　CHEN Jun,SUN Lei,HUI Jianrong,et al.Effect and mechanism of moxibustion on survival of triple negative breast cancer transplanted tumor mice[J].,2022,(11):819.[doi:DOI:10.3969/j.issn.1000-7369.2022.07.001]
[7]陈明明,郭 旭,熊乙霓,等.培元固本法治疗乳腺癌化疗后骨髓抑制临床研究[J].陕西中医,2022,(8):1049.[doi:DOI:10.3969/j.issn.1000-7369.2022.08.014]
[8]蔡丽珍,白瑞娜,张 路,等.基于“痰夹瘀血”理论探讨乳腺癌相关淋巴水肿因机治疗[J].陕西中医,2023,(10):1420.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.019]
　CAI Lizhen,BAI Ruina,ZHANG Lu,et al.Based on the theory of “phlegm blended with blood stasis”,to explore the mechanism and treatment of breast cancer related lymphedema[J].,2023,(11):1420.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.019]
[9]宋铁兵,李康乐,马 强,等.土贝母皂苷甲对乳腺癌细胞MCF-7凋亡的影响[J].陕西中医,2023,(11):1514.[doi:DOI:10.3969/j.issn.1000-7369.2023.11.004]
　SONG Tiebing,LI Kangle,MA Qiang,et al.Effect of Tubeimoside I on apoptosis of breast cancer cell MCF-7[J].,2023,(11):1514.[doi:DOI:10.3969/j.issn.1000-7369.2023.11.004]
[10]高 宏,周立江,邢向荣,等.柴胡龙骨牡蛎汤加减治疗乳腺癌研究进展[J].陕西中医,2023,(11):1657.[doi:DOI:10.3969/j.issn.1000-7369.2023.11.040]
　GAO Hong,ZHOU Lijiang,XING Xiangrong,et al.Research progress of Chaihu Longgu Muli decoction in treatment of breast cancer[J].,2023,(11):1657.[doi:DOI:10.3969/j.issn.1000-7369.2023.11.040]

更新日期/Last Update: 2019-11-15